8-K: Lineage Cell Therapeutics Reports Mixed 2025 Results

Lineage Cell Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant clinical and manufacturing advancements alongside increased net losses driven by non-cash expenses.

Summary

• Achieved the first milestone payment under the worldwide collaboration with Roche and Genentech for the OpRegen cell therapy program.
• Positive 36-month results from the RG6501 (OpRegen) Phase 1/2a clinical study were featured at Clinical Trials at the Summit 2025, suggesting sustained gains in visual acuity and structural support of the retina.
• Successfully demonstrated the high-scale production potential of the proprietary AlloSCOPE Manufacturing Platform, capable of producing millions of doses from a single cell line.
• Entered a research collaboration with William Demant Invest A/S to develop ReSonance (ANP1) for sensorineural hearing loss, with WDI contributing up to $12 million for preclinical development.
• Initiated a manufacturing scale research project (ILT1) focused on large-scale production of undifferentiated pluripotent cells for potential Type 1 Diabetes treatment.
• Treated the first chronic spinal cord injury (SCI) patient in the OPC1 DOSED Device Safety Study, with no significant safety events reported 180 days post-treatment.
• Reported total revenues of $14.6 million for the full year 2025, a net increase of $5.1 million compared to $9.5 million in 2024.
• Reported a net loss attributable to Lineage of $63.5 million, or $0.28 per share, for the full year 2025, compared to a net loss of $18.6 million, or $0.09 per share, for 2024.
• Cash, cash equivalents, and marketable securities totaled $55.8 million as of December 31, 2025, which, combined with approximate $5.4 million from warrant exercises in March 2026, is expected to support planned operations into Q2 2028.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update. While the full-year net loss significantly increased due to non-cash items, the company demonstrated strong operational and clinical progress across its pipeline and secured a solid cash runway, indicating continued strategic execution in a high-growth sector.

Positives

• Achieved the first milestone payment from the Roche/Genentech collaboration, validating manufacturing expertise and years of investment.
• OpRegen Phase 1/2a study showed consistent and durable treatment effects at 12, 24, and 36 months, with mean best corrected visual acuity (BCVA) scores above baseline for Cohort 4 patients.
• Five patients receiving significant OpRegen coverage across their geographic atrophy (GA) lesion demonstrated long-term outcomes consistent with meaningful disease stabilization and improvement.
• Successful completion of cGMP production runs for two product candidates using the AlloSCOPE platform, demonstrating capability for cost-effective, scalable, and consistent supply of millions of doses.
• New research collaboration with William Demant Invest A/S for ReSonance (ANP1) provides up to $12 million in funding for planned preclinical development activities over three years.
• Initiation of the ILT1 research initiative aims to solve a major hurdle to commercialization of islet cell therapy product candidates for Type 1 Diabetes by focusing on large-scale pluripotent cell production.
• The first chronic SCI participant in the OPC1 DOSED study was treated successfully with a novel delivery system, reporting no significant safety events 180 days post-treatment.
• Total revenues for the full year 2025 increased by $5.1 million to $14.6 million, primarily driven by higher collaboration revenue.
• Reported net income of $0.9 million, or $0.004 per share, for Q4 2025, an improvement from a net loss of $3.3 million in Q4 2024.
• Current cash and equivalents, including recent warrant proceeds, are expected to support operations into the second quarter of 2028, providing a solid financial runway.

Negatives

• The net loss attributable to Lineage for the full year 2025 significantly increased to $63.5 million, compared to $18.6 million in 2024.
• Total operating expenses for the full year 2025 increased substantially to $51.2 million from $31.0 million in 2024.
• A $14.8 million loss on impairment for the intangible asset related to the VAC platform was recognized during 2025.
• A significant non-cash fair value remeasurement expense of warrant liabilities of $37.9 million largely contributed to the increased net loss, primarily due to an increase in the company's share price.
• Research and development (R&D) expenses for the full year 2025 increased to $17.7 million from $12.5 million in 2024, driven by various program expenses.

Risks

• The company may need to allocate cash to unexpected events and expenses, potentially causing cash, cash equivalents, and marketable securities to be expended more quickly than expected.
• Development activities, preclinical activities, and clinical trials of product candidates may not commence, progress, or be completed as expected due to factors within and outside of the company's control.
• Positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies.
• Roche and Genentech may not successfully advance OpRegen cell therapy or be successful in completing further clinical trials and/or obtaining regulatory approval.
• Competing alternative therapies may adversely impact the commercial potential of OpRegen cell therapy.
• OPC1 clinical trials, including the DOSED study, may not be successful.
• Lineage's resubmission of its CLIN2 clinical grant application to CIRM may not be approved, which could adversely impact funding for the ongoing DOSED study.
• The ILT1 research initiative is in its early stages and may not successfully establish a production modality for large-scale islet cell production or result in a viable product candidate.
• The ongoing Israeli regional conflict may materially and adversely impact manufacturing processes, including cell banking and product manufacturing, conducted by the subsidiary in Jerusalem, Israel.
• Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice.

Future Outlook

Lineage Cell Therapeutics expects 2026 to be an exciting year focused on advancing therapeutic candidates, achieving key clinical and financial milestones, and enhancing manufacturing capabilities. The company aims to create a pipeline of cell-based assets, some for internal development and some for partnering, all based on its core AlloSCOPE technology. Cash and equivalents are projected to fund operations into the second quarter of 2028.

Management Comments

• "2025 was a very productive year for the Lineage team."
• "Our mission is to pioneer the emerging field of allogeneic cell therapy outside of oncology by applying our proprietary cell manufacturing technology platform, AlloSCOPE, to the production and transplantation of differentiated cell types."
• "Throughout 2025, we made meaningful progress in strengthening our scientific, operational and strategic foundations, and reported notable events in support of our mission."
• "2026 will be an exciting year as we advance our therapeutic candidates and pursue our long-term goal of creating a pipeline of similar cell-based assets, some of which we might choose to develop internally and some which we might seek to partner, but all based on our core technology and platform."
• "Our priorities in 2026 will include achieving key clinical and financial milestones, advancing our manufacturing capability, and maintaining the organizational focus necessary to execute with consistency against these goals."

Industry Context

StockSavvy.ai notes that Lineage Cell Therapeutics operates in the highly innovative and capital-intensive allogeneic cell therapy sector, a field with significant potential beyond oncology. The company's focus on conditions like geographic atrophy, spinal cord injury, and hearing loss positions it in areas with high unmet medical needs. The collaboration with Genentech and William Demant Invest A/S underscores the industry trend of strategic partnerships to de-risk development and leverage specialized manufacturing platforms like AlloSCOPE, which is critical for scalable and cost-effective cell therapy production.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders are impacted by the increased net loss (though largely non-cash), but also by positive clinical progress and an extended cash runway, indicating potential for future value creation.
• Patients are potential beneficiaries of advanced cell therapies for conditions like geographic atrophy, spinal cord injury, and hearing loss, addressing high unmet medical needs.
• Partners (Roche/Genentech, William Demant Invest A/S) benefit from continued collaboration, milestone achievements, and the advancement of partnered programs.
• Employees benefit from continued operational progress, strategic focus, and the company's commitment to pipeline development, providing stability and opportunities.

Next Steps

• Advance therapeutic candidates and pursue the long-term goal of creating a pipeline of cell-based assets in 2026.
• Achieve key clinical and financial milestones in 2026.
• Advance manufacturing capability in 2026.
• Maintain organizational focus to execute consistently against goals in 2026.
• Continue execution of Lineage's contributions to its collaboration with Roche and Genentech.
• The ongoing Phase 2a GAlette Study is currently enrolling at 17 clinical sites in the U.S. and Israel.
• Genentech plans to evaluate proprietary surgical delivery devices in the Phase 2a GAlette Study.
• Continue efforts under the services agreement with Genentech to support the Phase 1/2a study long-term follow-up and the GAlette Study, and provide technical training/materials for commercial manufacturing.
• Advance preclinical development of ReSonance (ANP1) over a three-year term, funded by WDI.
• CIRM continues to review Lineage's resubmitted CLIN2 grant application to support the DOSED study.

Key Dates

Recommendation

While Lineage Cell Therapeutics reported a significantly increased net loss for the full year 2025, this was primarily driven by non-cash items like warrant liability remeasurement and an impairment charge, rather than core operational deterioration. The company demonstrated substantial operational and clinical progress across its pipeline, including a key milestone payment from Genentech, positive long-term OpRegen data, and advancements in its manufacturing platform. The extended cash runway into Q2 2028 provides financial stability for ongoing development. Given the mixed financial results (strong Q4 net income, but large full-year net loss) alongside promising clinical and strategic advancements in a high-potential sector, a 'hold' recommendation is appropriate. Investors should monitor the progress of clinical trials and the impact of non-cash items on future financial statements.

Keywords

Cell Therapy, Biotechnology, Allogeneic, OpRegen, Geographic Atrophy, AMD, Spinal Cord Injury, OPC1, ReSonance, ANP1, Hearing Loss, AlloSCOPE, Manufacturing, Type 1 Diabetes, ILT1, Clinical Trials, Financial Results, LCTX, SEC Filing